Monaco Asset Management SAM Buys Shares of 75,000 Contineum Therapeutics, Inc. $CTNM

Monaco Asset Management SAM purchased a new position in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 75,000 shares of the company’s stock, valued at approximately $298,000. Monaco Asset Management SAM owned about 0.29% of Contineum Therapeutics as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. ADAR1 Capital Management LLC grew its holdings in Contineum Therapeutics by 105.2% during the first quarter. ADAR1 Capital Management LLC now owns 168,765 shares of the company’s stock valued at $1,178,000 after purchasing an additional 86,531 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Contineum Therapeutics during the 2nd quarter valued at $140,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Contineum Therapeutics during the 1st quarter worth $118,000. Nuveen LLC bought a new position in shares of Contineum Therapeutics during the 1st quarter worth $93,000. Finally, Strs Ohio purchased a new stake in Contineum Therapeutics in the 1st quarter worth about $27,000.

Contineum Therapeutics Trading Down 0.7%

CTNM stock opened at $10.93 on Friday. The firm has a 50 day moving average of $11.43 and a 200-day moving average of $7.32. The firm has a market capitalization of $306.50 million, a P/E ratio of -4.86 and a beta of 1.26. Contineum Therapeutics, Inc. has a 12 month low of $3.35 and a 12 month high of $20.24.

Contineum Therapeutics (NASDAQ:CTNM) last posted its earnings results on Thursday, October 30th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.13. Sell-side analysts predict that Contineum Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on CTNM shares. Leerink Partnrs raised shares of Contineum Therapeutics to a “strong-buy” rating in a report on Thursday, September 25th. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Monday, August 18th. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Leerink Partners began coverage on shares of Contineum Therapeutics in a report on Thursday, September 25th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Contineum Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).